[논문]Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States

Popovic, Jadranka; Geffner, Mitchell E.; Rogol, Alan D.; Silverman, Lawrence A.; Kaplowitz, Paul B.; Mauras, Nelly; Zeitler, Philip; Eugster, Erica A.; Klein, Karen O.

doi:10.3389/fped.2022.968485

Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States 원문보기

Frontiers in pediatrics, v.10, 2022년, pp.968485 -

Popovic, Jadranka (Department of Pediatric Endocrinology, Pediatric Institute, Allegheny Health Network , Pittsburgh, PA , United States) , Geffner, Mitchell E. (Department of Pediatric Endocrinology, Diabetes and Metabolism, The Saban Research Institute, Children's Hospital Los Angeles, Keck School of Medicine of the University of Southern California , Los Angeles, CA , United States) , Rogol, Alan D. (Department of Pediatric Diabetes and Endocrinology, University of Virginia , Charlottesville, VA , United States) , Silverman, Lawrence A. (Department of Pediatric Endocrinology, Goryeb Children's Hospital Atlantic Health , Morristown, NJ , United States) , Kaplowitz, Paul B. (Department of Endocrinology, Children's National Hospital , Washington, DC , United States) , Mauras, Nelly (Department of Pediatrics, Nemours Children's Health System , Jacksonville, FL , United States) , Zeitler, Philip (Department of Pediatric End) , Eugster, Erica A. , Klein, Karen O.

Abstract ▼ AI-Helper

Gonadotropin-releasing hormone agonists (GnRHa's) are the standard treatment for children with central precocious puberty (CPP). We aim to present data on available GnRHa options with an easy-to-review table and discuss factors that influence treatment selection. Five GnRHa's are currently FDA-approved and prescribed in the US and published data suggest similar safety and efficacy profiles over the first year of treatment. One- and 3-month intramuscular (IM) leuprolide acetate (LA) have long-term safety and efficacy data and allow for flexible dosing. Six-month IM triptorelin pamoate offers a longer duration of treatment, but without long-term efficacy and outcome data. Six-month subcutaneous (SQ) LA combines a SQ route of injection and long duration of action but lacks long-term efficacy and outcome data. The 12-month SQ histrelin acetate implant avoids injections and offers the longest duration of action, but requires a minor surgical procedure with local or general anesthesia. Factors in treatment selection include route of administration, needle size, injection volume, duration of action, and cost. The current GnRHa landscape provides options with varying benefits and risks, allowing physicians and caregivers to select the most appropriate therapy based on the specific needs and concerns of the child and the caregiver. Agents have different advantages and disadvantages for use, with no one agent displaying superiority.

주제어

참고문헌 (90)

1. Puberty and Precocious Puberty: Condition Information . National Institute of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development ( 2016 ).
2. Fuqua JS . Treatment and outcomes of precocious puberty: an update . J Clin Endocrinol Metab. ( 2013 ) 98 : 2198 – 207 . 10.1210/jc.2013-1024 23515450

상세보기
3. Kauli R Galatzer A Kornreich L Lazar L Pertzelan A Laron Z . Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or Gnrh analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method . Horm Res. ( 1997 ) 47 : 54 – 61 . 10.1159/000185432 9030968

상세보기
4. Pasquino AM Pucarelli I Accardo F Demiraj V Segni M Di Nardo R . Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function . J Clin Endocrinol Metab. ( 2008 ) 93 : 190 – 5 . 10.1210/jc.2007-1216 17940112

상세보기
5. Cassio A Cacciari E Balsamo A Bal M Tassinari D . Randomised trial of Lhrh analogue treatment on final height in girls with onset of puberty aged 75-85 years . Arch Dis Child. ( 1999 ) 81 : 329 – 32 . 10.1136/adc.81.4.329 10490438

상세보기
6. Antoniazzi F Zamboni G . Central precocious puberty: current treatment options . Paediatr Drugs. ( 2004 ) 6 : 211 – 31 . 10.2165/00148581-200406040-00002 15339200

상세보기
7. Blumenthal H Leen-Feldner EW Babson KA Gahr JL Trainor CD Frala JL . Elevated social anxiety among early maturing girls . Dev Psychol. ( 2011 ) 47 : 1133 – 40 . 10.1037/a0024008 21604866

상세보기
8. Carel JC Eugster EA Rogol A Ghizzoni L Palmert MR Antoniazzi F . Consensus statement on the use of gonadotropin-releasing hormone analogs in children . Pediatrics. ( 2009 ) 123 : e752 – 62 . 10.1542/peds.2008-1783 19332438

상세보기
9. Mensah FK Bayer JK Wake M Carlin JB Allen NB Patton GC . Early puberty and childhood social and behavioral adjustment . J Adolesc Health. ( 2013 ) 53 : 118 – 24 . 10.1016/j.jadohealth.2012.12.018 23558038

상세보기
10. Mendle J Ryan RM McKone KMP . Age at menarche, depression, and antisocial behavior in adulthood . Pediatrics. ( 2018 ) 141 : e20171703 . 10.1542/peds.2017-1703 29279324

상세보기
11. Klein KO Soliman AM Grubb E Nisbet P . A survey of care pathway and health-related quality of life impact for children with central precocious puberty . Curr Med Res Opin. ( 2020 ) 36 : 411 – 8 . 10.1080/03007995.2019.1699517 31778082

상세보기
12. Yang H Luo S Liang X Lin Q Cheng T Zeng L . The Association between family impact and health-related quality of life of children with idiopathic central precocious puberty in Chongqing, China . Health Qual Life Outcomes. ( 2021 ) 19 : 171 . 10.1186/s12955-021-01805-w 34174889

상세보기
13. Lupron Depot-Ped ® (Leuprolide Acetate for Depot Suspension) [Prescribing Information] . AbbVie Inc . ( 1993 ).
14. LUPRON . Lupron Depot (Leuprolide Acetate for Depot Suspension) [Prescription Information] . FDA ( 2011 ).
15. Triptodur ® (Triptorelin) [Prescribing Information] . Arbor Pharmaceuticals, LLC ( 2017 ).
16. Fensolvi ® (Leuprolide Acetate) for Injectable Suspension for Subcutaneous Use [Prescribing Information] . Tolmar Pharmaceuticals, Inc . ( 2020 ).
17. Supprelin ® La (Histrelin Acetate) Subcutaneous Implant [Prescribing Information] . Endo Pharmaceuticals Inc . ( 2011 ).
18. Synarel ® (Nafarelin Acetate) Nasal Solution [Prescribing Information] . Skokie, IL: Searle ( 1998 ).
19. Bangalore Krishna K Fuqua JS Rogol AD Klein KO Popovic J Houk CP . Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium . Horm Res Paediatr. ( 2019 ) 91 : 357 – 72 . 10.1159/000501336 31319416

상세보기
20. Lee HS Yoon JS Park KJ Hwang JS . Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty . PLoS ONE. ( 2018 ) 13 : e0201906 . 10.1371/journal.pone.0201906 30133462

상세보기
21. Varni JW Burwinkle TM Lane MM . Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application . Health Qual Life Outcomes. ( 2005 ) 3 : 34 . 10.1186/1477-7525-3-34 15904527

상세보기
22. Neely EK Lee PA Bloch CA Larsen L Yang D Mattia-Goldberg C . Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery . Int J Pediatr Endocrinol. ( 2010 ) 2010 : 398639 . 10.1186/1687-9856-2010-398639 21437000
23. Lee PA Neely EK Fuqua J Yang D Larsen LM Mattia-Goldberg C . Efficacy of leuprolide acetate 1-month depot for central precocious puberty (Cpp): growth outcomes during a prospective, longitudinal study . Int J Pediatr Endocrinol. ( 2011 ) 2011 : 7 . 10.1186/1687-9856-2011-7 21860633

상세보기
24. Lee PA Klein K Mauras N Neely EK Bloch CA Larsen L . Efficacy and safety of leuprolide acetate 3-month Depot 1125 milligrams or 30 milligrams for the treatment of central precocious puberty . J Clin Endocrinol Metab. ( 2012 ) 97 : 1572 – 80 . 10.1210/jc.2011-2704 22344198

상세보기
25. Histrelin Subcutaneous Implant in Children With Central Precocious Puberty . ( 2021 ). ClinicalTrials.gov . Available online at: https://clinicaltrials.gov/ct2/show/NCT00779103 (accessed October 21, 2021).
26. Klein K Yang J Aisenberg J Wright N Kaplowitz P Lahlou N . Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty . J Pediatr Endocrinol Metab. ( 2016 ) 29 : 1241 – 8 . 10.1515/jpem-2015-0376 26887034

상세보기
27. Klein KO Freire A Gryngarten MG Kletter GB Benson M Miller BS . Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty . J Clin Endocrinol Metab. ( 2020 ) 105 : e3660 – 671 . 10.1210/clinem/dgaa479 34000029

상세보기
28. Silverman LA Neely EK Kletter GB Lewis K Chitra S Terleckyj O . Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial . J Clin Endocrinol Metab. ( 2015 ) 100 : 2354 – 63 . 10.1210/jc.2014-3031 25803268

상세보기
29. Ferguson J Hockley J Tiplady R Burns C . WHO International Collaborative Study of the Proposed 5th International Standard for Human, Urinary Follicle-Stimulating Hormone and Human, Urinary Luteinizing Hormone, for Bioassay . Geneva : World Health Organization ( 2012 ).
30. Ferguson J Hockley J Burns C . WHO International Collaborative Study of the Proposed 3rd International Standard for Human, Pituitary Luteinizing Hormone . Geneva : World Health Organization ( 2014 ).
31. Klein KO Baron J Barnes KM Pescovitz OH Cutler GB Jr . Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist . J Clin Endocrinol Metab. ( 1998 ) 83 : 2387 – 9 . 10.1210/jcem.83.7.4929 9661615
32. Popovic J . Data From: A Review of Current Therapies for Children with Central Precocious Puberty. Different International Unit Versions Are Not Comparable. Cambridge, MA : Harvard Dataverse ( 2022 ).
33. Vargas Trujillo M Dragnic S Aldridge P Klein KO . Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years . J Pediatr Endocrinol Metab. ( 2021 ) 34 : 733 – 9 . 10.1515/jpem-2021-0114 33856747

상세보기
34. Lee PA Klein K Mauras N Lev-Vaisler T Bacher P . 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty . J Clin Endocrinol Metab. ( 2014 ) 99 : 3153 – 9 . 10.1210/jc.2013-4471 24926950

상세보기
35. Eugster EA Clarke W Kletter GB Lee PA Neely EK Reiter EO . Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial . J Clin Endocrinol Metab. ( 2007 ) 92 : 1697 – 704 . 10.1210/jc.2006-2479 17327379

상세보기
36. Neely EK Silverman LA Geffner ME Danoff TM Gould E Thornton PS . Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy . Int J Pediatr Endocrinol. ( 2013 ) 2013 : 20 . 10.1186/1687-9856-2013-20 24295437

상세보기
37. Hirsch HJ Gillis D Strich D Chertin B Farkas A Lindenberg T . The histrelin implant: a novel treatment for central precocious puberty . Pediatrics. ( 2005 ) 116 : e798 – 802 . 10.1542/peds.2005-0538 16322137

상세보기
38. Lewis KA Goldyn AK West KW Eugster EA A . Single histrelin implant is effective for 2 years for treatment of central precocious puberty . J Pediatr. ( 2013 ) 163 : 1214 – 6 . 10.1016/j.jpeds.2013.05.033 23809043

상세보기
39. Okada H . One- and three-month release injectable microspheres of the Lh-Rh superagonist leuprorelin acetate . Adv Drug Deliv Rev. ( 1997 ) 28 : 43 – 70 . 10.1016/S0169-409X(97)00050-1 10837564

상세보기
40. Okada H Doken Y Ogawa Y Toguchi H . Preparation of rhree-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers . Pharm Res. ( 1994 ) 11 : 1143 – 7 . 10.1023/A:1018936815654 7971715

상세보기
41. Thakare EB Malpure PS Maru AD Surana S . Atrigel-implants and controlled release drug delivery system: a review . Am J PharmTech Res. ( 2019 ) 9 : 134 – 46 . 10.46624/ajptr.2019.v9.i2.013

상세보기
42. Donnelly S Shuriff D Stylianos S Zitsman J . Severe allergic reaction following histrelin implant (supprelin la) . JPS Case Rep. ( 2015 ) 3 : 523 – 5 . 10.1016/j.epsc.2015.10.001

상세보기
43. Eugster EA . Experience with the histrelin implant in pediatric patients . Endocr Dev. ( 2016 ) 30 : 54 – 9 . 10.1159/000439330 26683629
44. Swendiman RA Vogiatzi MG Alter CA Nance ML . Histrelin implantation in the pediatric population: a 10-year institutional experience . J Pediatr Surg. ( 2019 ) 54 : 1457 – 61 . 10.1016/j.jpedsurg.2018.08.048 30262200

상세보기
45. Monroe BJ Fallon SC Brandt ML . Intraoperative sonographic localization of a fractured supprelin implant in a pediatric patient: a case report . J Pediatr Endocrinol Metab. ( 2012 ) 25 : 167 – 9 . 10.1515/jpem.2011.432 22570970

상세보기
46. Davis JS Alkhoury F Burnweit C . Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty . J Pediatr Surg. ( 2014 ) 49 : 807 – 10 . 10.1016/j.jpedsurg.2014.02.067 24851775

상세보기
47. Rahhal S Clarke WL Kletter GB Lee PA Neely EK Reiter EO . Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty . Int J Pediatr Endocrinol. ( 2009 ) 2009 : 812517 . 10.1186/1687-9856-2009-812517 19956699
48. Silverman L Brenner D Cerame B Phillips S Stred S . Partially retained supprelin implant leads to continuous pubertal supression . Horm Res Paediatr. ( 2020 ) 93 : 1 – 185 .
49. Krishnaraj B Adhikari A Taha D Thirunagari R Senguttuvan R . Sat-298 a case of a forgotten histrelin acetate implant: can histrelin acetate implants be used for more than a year? J Endocr Soc. ( 2019 ) 3 ( Suppl 1 ). 10.1210/js.2019-SAT-298

상세보기
50. Villalta D Quintos JB . Gonadotropin suppression for 7 years after a single histrelin implant for precocious puberty . J Endocr Soc. ( 2022 ) 6 : bvab189 . 10.1210/jendso/bvab189 35047716

상세보기
51. Lee JW Kim HJ Choe YM Kang HS Kim SK Jun YH . Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty . Ann Pediatr Endocrinol Metab. ( 2014 ) 19 : 135 – 40 . 10.6065/apem.2014.19.3.135 25346917

상세보기
52. Miller BS Shukla AR . Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists . Clin Ther. ( 2010 ) 32 : 1749 – 51 . 10.1016/j.clinthera.2010.09.009 21194598

상세보기
53. Johnson SR Nolan RC Grant MT Price GJ Siafarikas A Bint L . Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty . J Paediatr Child Health. ( 2012 ) 48 : E136 – 9 . 10.1111/j.1440-1754.2011.02083.x 21564386

상세보기
54. Tonini G Marinoni S Forleo V Rustico M . Local reactions to luteinizing hormone releasing hormone analog therapy . J Pediatr. ( 1995 ) 126 : 159 – 60 . 10.1016/S0022-3476(95)70534-1 7815213

상세보기
55. McGarvey MA . Intramuscular injections: a review of nursing practices for adults. All Ireland . J Nurs Midwifery. ( 2001 ) 1 : 185 – 93 . 18454829
56. Kirouac NPE . A Nursing Perspective: Best Practices for Pubertal Suppression for Individuals with Central Precocious Puberty and Transgender . Paris : ESPE ( 2016 ).
57. Perry APP Ostendorf W . Clinical Nursing Skills and Techniques. 9th ed. Mosby ( 2017 ). 26 p.
58. Lawson ML Cohen N . A Single sample subcutaneous luteinizing hormone (Lh)-releasing hormone (Lhrh) stimulation test for monitoring Lh suppression in children with central precocious puberty receiving Lhrh agonists . J Clin Endocrinol Metab. ( 1999 ) 84 : 4536 – 40 . 10.1210/jc.84.12.4536 10599714
59. Armenta AM Jaquez SD Levy ML Diaz LZ . Use of psychologic strategies to reduce pain and anxiety related to dermatology procedures . Pediatr Dermatol. ( 2019 ) 36 : 416 – 7 . 10.1111/pde.13739 30739337

상세보기
60. McMurtry CM Noel M Taddio A Antony MM Asmundson GJ Riddell RP . Interventions for individuals with high levels of needle fear: systematic review of randomized controlled trials and quasi-randomized controlled trials . Clin J Pain. ( 2015 ) 31 : S109 – 23 . 10.1097/AJP.0000000000000273 26352916

상세보기
61. Nagai Y Ohshige T Arai K Kobayashi H Sada Y Ohmori S . Comparison between shorter straight and thinner microtapered insulin injection needles . Diabetes Technol Ther. ( 2013 ) 15 : 550 – 5 . 10.1089/dia.2012.0334 23621793

상세보기
62. Schwartz S Hassman D Shelmet J Sievers R Weinstein R Liang J. . A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge X 6 Mm Needle Versus a 29 Gauge X 127 Mm needle in obese patients with diabetes mellitus . Clin Ther . ( 2004 ) 26 : 1663 – 78 . 10.1016/j.clinthera.2004.10.007 15598483

상세보기
63. Miyakoshi M Kamoi K Iwanaga M Hoshiyama A Yamada A . Comparison of patient's preference, pain perception, and usability between micro fine plus 31-gauge needle and microtapered nanopass 33-gauge needle for insulin therapy . J Diabetes Sci Technol. ( 2007 ) 1 : 718 – 24 . 10.1177/193229680700100516 19885140

상세보기
64. Arendt-Nielsen L Egekvist H Bjerring P . Pain following controlled cutaneous insertion of needles with different diameters . Somatosens Mot Res. ( 2006 ) 23 : 37 – 43 . 10.1080/08990220600700925 16846958

상세보기
65. General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Ppactices (Acip) . Centers for Disease Control and Prevention . Advisory Committee on Immunization Practices ( 2020 ).
66. Prettyman J EL Boldt-Houle D Atkinson S Wilt W . Personalizing treatment in the delivery of care by nurses to patients with prostate cancer . J Urol Nursing. ( 2019 ) 39 : 83 – 99 . 10.7257/1053-816X.2019.39.2.83

상세보기
67. Bowden VR Greenberg CS . Medication Administration: Intramuscular . Pediatric Nursing Procedures . Philadelphia, PA : Lippincott, Williams, & Wilkins ( 2003 ). p. 374 – 5 .
68. Zijlstra E Jahnke J Fischer A Kapitza C Forst T . Impact of injection speed, volume, and site on pain sensation . J Diabetes Sci Technol. ( 2018 ) 12 : 163 – 8 . 10.1177/1932296817735121 28990437

상세보기
69. Hankin C Bronstone A Wang Z editors . Adherence to Monthly Injectable Leuprolide Acetate among Florida Medicaid-Enrolled Children with Central Precocious Puberty . In: 42nd Midyear Clinical Meeting of the American Society of Health-System Pharamacists . Las Vegas, Nevada ( 2007 ).
70. Lerwick JL . Minimizing pediatric healthcare-induced anxiety and trauma . World J Clin Pediatr. ( 2016 ) 5 : 143 – 50 . 10.5409/wjcp.v5.i2.143 27170924

상세보기
71. Kunz GJ Sherman TI Klein KO . Luteinizing hormone (Lh) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection Lh levels useful in monitoring treatment? J Pediatr Endocrinol Metab. ( 2007 ) 20 : 1189 – 98 . 10.1515/JPEM.2007.20.11.1189 18183790

상세보기
72. Kaplowitz P Bloch C . Evaluation and referral of children with signs of early puberty . Pediatrics. ( 2016 ) 137 : e20153732 . 10.1542/peds.2015-3732 26668298

상세보기
73. Klein KO Lee PA . Gonadotropin-releasing hormone (Gnrha) therapy for central precocious puberty (Cpp): review of nuances in assessment of height, hormonal suppression, psychosocial issues, and weight gain, with patient examples . Pediatr Endocrinol Rev. ( 2018 ) 15 : 298 – 312 . 10.17458/per.vol15.2018.kl.GnRHaforCPP 29806750
74. Mitamura R Yano K Suzuki N Ito Y Makita Y Okuno A . Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol secretion before the onset of female puberty in short children * . J Clin Endocrinol Metab. ( 2000 ) 85 : 1074 – 80 . 10.1210/jc.85.3.1074 10720042
75. Carel JC Roger M Ispas S Tondu F Lahlou N Blumberg J . Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French Study Group of Decapeptyl in Precocious Puberty . J Clin Endocrinol Metab. ( 1999 ) 84 : 1973 – 8 . 10.1210/jcem.84.6.5647 10372696

상세보기
76. Ohyama K Tanaka T Tachibana K Niimi H Fujieda K Matsuo N . Timing for discontinuation of treatment with a long-acting gonadotropin-releasing hormone analog in girls with central precocious puberty. Tap-144sr Cpp Study Group . Endocr J. ( 1998 ) 45 : 351 – 6 . 10.1507/endocrj.45.351 9790269

상세보기
77. Klein K Soliman AM Bonafede M Nelson JK Grubb E . Health care utilization and economic burden in patients with central precocious puberty: an assessment of the commercially insured and medicaid populations . J Manag Care Spec Pharm. ( 2019 ) 25 : 836 – 46 . 10.18553/jmcp.2019.25.7.836 31232203

상세보기
78. Yamasaki H Douchi T Yamamoto S Oki T Kuwahata R Nagata Y . Body fat distribution and body composition during Gnrh agonist therapy . Obstet Gynecol. ( 2001 ) 97 : 338 – 42 . 10.1097/00006250-200103000-00003 11239633

상세보기
79. Chen M Eugster EA . Central precocious puberty: update on diagnosis and treatment . Paediatr Drugs. ( 2015 ) 17 : 273 – 81 . 10.1007/s40272-015-0130-8 25911294

상세보기
80. Martinerie L de Mouzon J Blumberg J di Nicola L Maisonobe P Carel JC . Fertility of women treated during childhood with triptorelin (Depot formulation) for central precocious puberty: the prefer study . Horm Res Paediatr. ( 2020 ) 93 : 529 – 38 . 10.1159/000513702 33774631

상세보기
81. Tanaka T Niimi H Matsuo N Fujieda K Tachibana K Ohyama K . Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The Tap-144-Sr Japanese Study Group on Central Precocious Puberty . J Clin Endocrinol Metab. ( 2005 ) 90 : 1371 – 6 . 10.1210/jc.2004-1863 15598675

상세보기
82. Bertelloni S Baroncelli GI Ferdeghini M Menchini-Fabris F Saggese G . Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues . Eur J Pediatr. ( 2000 ) 159 : 369 – 74 . 10.1007/s004310051289 10834524

상세보기
83. van der Sluis IM Boot AM Krenning EP Drop SLS de Muinck Keizer-Schrama SMPF . Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of Gnrh agonist therapy . J Clin Endocrinol Metab. ( 2002 ) 87 : 506 – 12 . 10.1210/jcem.87.2.8202 11836277

상세보기
84. Unal O Berberoglu M Evliyaoglu O Adiyaman P Aycan Z Ocal G . Effects on bone mineral density of gonadotropin releasing hormone analogs used in the treatment of central precocious puberty . J Pediatr Endocrinol Metab. ( 2003 ) 16 : 407 – 11 . 10.1515/JPEM.2003.16.3.407 12705366

상세보기
85. Heger S Müller M Ranke M Schwarz HP Waldhauser F Partsch CJ . Long-term Gnrh agonist treatment for female central precocious puberty does not impair reproductive function . Mol Cell Endocrinol. ( 2006 ) 254– 55 : 217 – 20 . 10.1016/j.mce.2006.04.012 16757104

상세보기
86. Lazar L Lebenthal Y Yackobovitch-Gavan M Shalitin S de Vries L Phillip M . Treated and untreated women with idiopathic precocious puberty: Bmi evolution, metabolic outcome, and general health between third and fifth decades . J Clin Endocrinol Metab. ( 2015 ) 100 : 1445 – 51 . 10.1210/jc.2014-3748 25650898

상세보기
87. Collaborative Group on Hormonal Factors in Breast Cancer . Menarche, menopause, and BREAST cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies . Lancet Oncol. ( 2012 ) 13 : 1141 – 51 . 10.1016/S1470-2045(12)70425-4 23084519

상세보기
88. Goldberg M D'Aloisio AA O'Brien KM Zhao S Sandler DP . Pubertal timing and breast cancer risk in the sister study cohort . Breast Cancer Research. ( 2020 ) 22 : 112 . 10.1186/s13058-020-01326-2 33109223

상세보기
89. Tremblay L Frigon JY . Precocious puberty in adolescent girls: a biomarker of later psychosocial adjustment problems . Child Psychiatry Hum Dev. ( 2005 ) 36 : 73 – 94 . 10.1007/s10578-004-3489-2 16049645

상세보기
90. Wojniusz S Callens N Sütterlin S Andersson S De Schepper J Gies I . Cognitive, emotional, and psychosocial functioning of girls treated with pharmacological puberty blockage for idiopathic central precocious puberty . Front Psychol. ( 2016 ) 7 : 1053 . 10.3389/fpsyg.2016.01053 27462292

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (90)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트